Business, energy, technology, markets and global industry news from Business News Today

Parkinson’s disease

PharmaDeviceNews Parkinson’s disease
Representative image of brain-targeted drug discovery and AI-designed molecular structures, highlighting the promise of next-generation NLRP3 inhibitors like ISM8969 in treating CNS diseases.
Pharma & Biotech

Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases

Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to

Read More
Pharma & Biotech

iRegene’s NouvNeu001 becomes first iPSC therapy with RMAT and Fast Track designations

Find out how iRegene’s iPSC-based Parkinson’s therapy NouvNeu001 became the first to earn both RMAT and Fast Track status from the FDA.

Read More
Pharma & Biotech

Can Amneal’s Parkinson’s strategy evolve beyond symptoms? KeifeRx tie-up may signal shift

KeifeRx and Amneal join forces on KFRX06, a brain-penetrant LRRK2 inhibitor for Parkinson’s. Find out what this could mean for CNS innovation.

Read More
Pharma & Biotech

Ventyx to give Lilly an oral inflammation pipeline—what’s the real upside?

Eli Lilly and Company has announced plans to acquire Ventyx Biosciences Inc. in an all-cash transaction valued at approximately $1.2 billion, securing a portfolio of clinical-stage oral small molecule therapeutics focused on chronic inflammatory-mediated diseases. The deal includes NLRP3 inhibitors such as VTX2735 and VTX3232, alongside two Phase 2 programs for inflammatory bowel disease. The

Read More
Pharma & Biotech

From Parkinson’s to platform scalability: What’s next for Sinopia’s LEADS technology

Sinopia Biosciences receives NIH grant to expand its LEADS platform. Find out how AI and metabolomics could transform drug discovery.

Read More
Representative image illustrating intracellular drug delivery into neurons, reflecting how Mercury Bio Inc. and Meta‑Flux are exploring AI‑guided large‑molecule therapies to target Parkinson’s disease and Alzheimer’s disease at the cellular level.
Pharma & Biotech

Meta-Flux and Mercury Bio team up to target intracellular CNS pathways with precision

Mercury Bio Inc., a biotechnology company focused on large-molecule therapeutics, has announced a strategic collaboration with Meta-Flux, a disease simulation company that leverages artificial intelligence, to advance drug discovery programs for Parkinson’s disease and Alzheimer’s disease. The partnership combines Mercury Bio’s proprietary yeast extracellular vesicle (yEV) delivery technology with Meta-Flux’s disease-scale computational modeling platform, with

Read More
Medical Devices & Diagnostics

What the nanoparticle BCI model reveals about the future of brain interfaces

Subsense, Inc. has raised an additional $10 million in funding to accelerate the development of its non-surgical, nanoparticle-based brain-computer interface (BCI), bringing its total funding to $27 million. The financing, led by Golden Falcon Capital, follows early successes in nanoparticle design, in vitro signal stimulation, and the construction of a bio-integrated hardware-software platform intended to

Read More
Lee’s Pharmaceutical acquires U.S. manufacturing base in Staccato platform buy
Pharma & Biotech

How Staccato technology positions Lee’s Pharmaceutical for CNS drug delivery leadership

Lee’s Pharmaceutical Holdings Limited has acquired the Staccato One Breath Technology platform and related assets from Alexza Pharmaceuticals, gaining exclusive rights to manufacture and license Staccato alprazolam under its global agreement with UCB. The transaction expands Lee’s Pharmaceutical’s inhalation drug delivery pipeline, deepens its foothold in central nervous system therapies, and positions the company to

Read More